CPD Accredited Podcast series
Risk! Evidence! Guidelines! Fine tuning type 2 diabetes management in adults
Don't forget...
We value your feedback and would appreciate your help in shaping future podcasts. After listening, click here to complete the evaluation form.
You can also download your CPD certificate from each podcast page. This allows you to record your learning reflections in support of your professional revalidation.
Featured episode
Early adoption in primary care of cardiorenal metabolic medicines in adult type 2 diabetes
Chair: Dr Lavan Baskaran
Speaker: Shivani Patel
Other episodes
How has the management of adult type 2 diabetes changed in recent decades?
Speaker: Professor Mike Cummings
What tools are available to assess cardiovascular risk in adult type 2 diabetes?
Speaker: Professor Ahmet Fuat
GP and Director. Croydon GP Collaborative, Croydon and the James O'Riordan Medical Centre, Sutton
GP with a specialist interest in cardiology
Consultant in Diabetes and Endocrinology, Portsmouth NHS Trust, and Honorary Professor in Diabetes and Endocrinology, Portsmouth University
Lead Clinical Pharmacist, Haringey GP Federation, London
PC-GB-111728 | July 2025
The content on this website is in relation to adult patients.
Empagliflozin is not recommended in severe hepatic impairment, breastfeeding, Type 1 diabetes and is contraindicated in patients with hypersensitivity to the active ingredient or any of its excipients. Empagliflozin should be avoided in pregnancy.
Please consult the SmPC for full details regarding adverse events, monitoring requirements and interactions prior to prescribing JARDIANCE®.
- JARDIANCE® (empagliflozin) UK Summary of Product Characteristics (SmPC). Available at:
http://www.medicines.org.uk/emc/medicine/28973.
JARDIANCE® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes1
JARDIANCE® is indicated in adults for the treatment of chronic kidney disease.1
JARDIANCE® is indicated in adults for the treatment of symptomatic chronic heart failure.1
PC-GB-109995 V4 | October 2025